Reviewing GoodRx (NASDAQ:GDRX) & Information Analysis (OTCMKTS:IAIC)

Information Analysis (OTCMKTS:IAIC) and GoodRx (NASDAQ:GDRX) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, valuation, dividends, profitability, institutional ownership, earnings and analyst recommendations.

Earnings and Valuation

This table compares Information Analysis and GoodRx”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Information Analysis	$13.90 million	0.00	$410,000.00	$0.04	N/A
GoodRx	$796.85 million	1.44	$30.44 million	$0.06	55.67

GoodRx has higher revenue and earnings than Information Analysis. Information Analysis is trading at a lower price-to-earnings ratio than GoodRx, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

63.8% of GoodRx shares are held by institutional investors. 23.8% of Information Analysis shares are held by company insiders. Comparatively, 5.9% of GoodRx shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Information Analysis and GoodRx’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Information Analysis	3.72%	18.48%	9.33%
GoodRx	2.61%	7.90%	3.23%

Analyst Ratings

This is a summary of recent recommendations and price targets for Information Analysis and GoodRx, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Information Analysis	0	0	0	0	0.00
GoodRx	3	7	5	0	2.13

GoodRx has a consensus price target of $3.81, suggesting a potential upside of 14.15%. Given GoodRx’s stronger consensus rating and higher possible upside, analysts clearly believe GoodRx is more favorable than Information Analysis.

Volatility and Risk

Information Analysis has a beta of 3.25, suggesting that its stock price is 225% more volatile than the S&P 500. Comparatively, GoodRx has a beta of 1.6, suggesting that its stock price is 60% more volatile than the S&P 500.

Summary

GoodRx beats Information Analysis on 7 of the 13 factors compared between the two stocks.

About Information Analysis

Information Analysis, Inc. provides information technology services. The firm engages in the business of modernizing client information systems, developing and maintaining information technology systems, and performing consulting services to government and commercial organizations. It specializes in legacy systems modernization, ebusiness solutions, enterprise portals, system migration and re-hosting services, and enterprise application integration. The company was founded by Sandor Rosenberg in 1979 and is headquartered in Fairfax, VA.

About GoodRx

GoodRx Holdings, Inc., together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices. It also offers other healthcare products and services, including subscriptions, and pharma manufacturer solutions, as well as telehealth services through the GoodRx Care platform. It serves pharmacy benefit managers who manage formularies and prescription transactions, including establishing pricing between consumers and pharmacies. The company was founded in 2011 and is headquartered in Santa Monica, California.